DTaP-polio combo vaccine does well in Phase III trials

Article

Positive Phase III results from a vaccine that combines four existing immunizations together were reported online by Pediatric Infectious Disease Journal.

Positive Phase III results from a vaccine that combines four existing immunizations together were reported online by Pediatric Infectious Disease Journal.

Kinrix is GlaxoSmithKline's name for a combination of inactivated polio and a DTaP (diphtheria, tetanus, and acellular pertussis) vaccinations. The combined product would require one shot, not two.

The phase III results showed immune response and safety profile to the individually-administered shots. It enrolled over 4,000 children ages 4 to 6. The most common adverse event was injection site pain (over 50%, followed by redness, swelling, and increase in arm circumference (all over 25%).

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
© 2025 MJH Life Sciences

All rights reserved.